Orexigen (OREX) is +152% premarket after an FDA advisory panel voted 13-7 to recommend the...


Orexigen (OREX) is +152% premarket after an FDA advisory panel voted 13-7 to recommend the approval of diet drug Contrave. The decision came as a surprise, as the FDA has set a very high bar for diet drugs and already rejected several other obesity treatments this year. Rivals gaining on the news: VVUS +12.8%, ARNA +9.9%.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs